ArticleFrontiers in medicine2025
Comparative effectiveness of dual-focus contact lenses and DIMS spectacle lenses for myopia control in patients with low astigmatism: a retrospective study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate and compare the effectiveness of dual-focus contact lenses (DFCL) and defocus incorporated multiple segment (DIMS) spectacle lenses in controlling myopia progression in patients with low astigmatism. Methods: A retrospective cohort study was conducted involving myopic patients with astigmatism of less than -1.25 diopters (D) who used either DFCL or DIMS spectacle lenses. The study included 95 eyes in the DFCL group and 88 eyes in the DIMS group, and the spherical equivalent refraction (SER) of the study population ranged from -0.50 D to -6.00 D. The primary outcomes were the progression of SER and the elongation of axial length (AXL) over 1 year. A generalized linear mixed model was used to calculate adjusted odds ratios (aORs) and the associated 95% confidence intervals (CIs), adjusting for age, sex, initial AXL, and initial SER. Results: The mean SER progression was -0.28 ± 0.15 D in the DFCL group and -0.25 ± 0.12 D in the DIMS group ( Conclusion: The use of DIMS spectacle lenses showed SER and AXL control similar to that of DFCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.